and Private Practice, Niagara Falls (PS), New York Purpose: We evaluated the efficacy of the web based P3P (Personal Patient Profile-Prostate) decision aid vs usual care with regard to decisional conflict in men with localized prostate cancer. Materials and Methods: A randomized (1:1), controlled, parallel group, nonblinded trial was performed in 4 regions of the United States. Eligible men had clinically localized prostate cancer and an upcoming consultation, and they spoke and read English or Spanish. Participants answered questionnaires to report decision making stage, personal characteristics, concerns and preferences plus baseline symptoms and decisional conflict. A randomization algorithm allocated participants to receive tailored education and communication coaching, generic teaching sheets and external websites plus a 1-page summary to clinicians (intervention) or the links plus materials provided in clinic (usual care). Conflict outcomes and the number of consultations were measured at 1 month. Univariate and multivariable models were used to analyze outcomes. Results: A total of 392 men were randomized, including 198 to intervention and 194 to usual care, of whom 152 and 153, respectively, returned 1-month outcomes. The mean AE SD 1-month decisional conflict scale (score range 0 to 100) was 10.9 AE 16.7 for intervention and 9.9 AE 18.0 for usual care. The multivariable model revealed significantly reduced conflict in the intervention group (e5.00, 95% CI e9.40ee0.59). Other predictors of conflict included income, marital or partner status, decision status, number of consultations, clinical site and D'Amico risk classification. Conclusions: In this multicenter trial the decision aid significantly reduced decisional conflict. Other variables impacted conflict and modified the effect of the decision aid, notably risk classification, consultations and resources. P3P is an effective adjunct for shared decision making in men with localized prostate cancer.
THE AUA (American Urological Association) 2017 guidelines for clinically LPC begin with counseling patients and incorporating shared decision making followed by recommendations for appropriate active surveillance and active therapies. 1 Men are increasingly engaging in active surveillance of LPC. 2, 3 For men seeking treatment there are several options, including prostatectomy, external beam radiotherapy, brachytherapy and hormonal therapy. Consulting physicians are challenged to present options with equipoise. 4, 5 Choosing a course of action for LPC is challenging, and DC and uncertainty experienced by men have been documented. 6e9 There is evidence that men make a decision by considering personal preferences and factors. 6, 10, 11 Yet evidence exists that clinicians make decisions often without soliciting patient preferences. 12 Our team tested P3P from 2007 to 2009 as a preparatory adjunct to the face-to-face consultation. 9 Although we found that P3P users reported significantly lower conflict related to uncertainty and value clarification during the months after enrollment, outcomes were influenced by the number of pre-enrollment consultations that men experienced, 13 internet use, race and income.
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P3P was revised to accommodate low literacy users and tested in minority men during decision making. 14 We designed a subsequent randomized trial and performed the study in health networks in geographically distinct regions of the United States.
MATERIALS AND METHODS
The primary objective of this randomized, controlled (1:1), parallel group, nonblinded trial was to compare decisional conflict between 2 groups, including 1) P3P decision support intervention plus usual education and 2) usual education plus links to reputable websites. Secondary objectives were to compare decisional regret and satisfaction at 6 months. We present the decisional conflict comparison 1 month after study enrollment.
Sample and Settings
Eligible men had 1) biopsy proven cT1 or cT2 prostate cancer of any risk level (a criterion that biopsy was performed at enrolling sites was removed 1 year after enrollment to increase accrual rates), 2) an upcoming consultation at an enrolling site and 3) self-reported ability to read and understand English or Spanish. We excluded men whose records documented any of certain elements, including 1) more than 1 consultation visit, 2) a final care decision or 3) active surveillance had begun or any prostate cancer treatment had been received. The study was approved by the Dana-Farber/Harvard Cancer Center institutional review board and the review board at each site.
Procedures
Research assistants recruited eligible participants by telephone and offered the opportunity of home access or access on an iPadÒ in clinic before the consultation appointment.
Home users agreed to elements of consent online prior to the baseline questionnaire and then signed written consent at the clinic visit. At the Kaiser PermanenteÒ site full consent was completed online. Content was delivered securely using open source software for computerized patient reported outcomes (http://cprohealth.org).
At the baseline session the P3P website presented 1) questionnaires 9, 15 for which responses were used to create the intervention component, including influential personal factors, decision making stage, decisional control preference, prostate cancer symptoms, age and ethnicity or race and 2) study measures, including DC, 16 income, education level and health care utilization variables. After baseline questionnaires were submitted participants were randomized to the intervention or the UC group in permuted blocks of 4 as stratified by clinic site via an algorithm embedded in the software.
Personal Patient Profile-Prostate Intervention
Participants randomized to P3P were presented with the online intervention comprising education and communication coaching in the form of text, graphs and short video clips on medical facts and personally relevant factors for the prostate cancer decision plus printed teaching sheets as in the prior trial. 9, 15 Informational topics and tailoring to race, ethnicity and age algorithms in P3P were previously described. 15 Based on usability testing after the first trial, 14, 17 the software was enhanced with navigation guidance, key term definitions, larger widgets and context sensitive help. Content was updated by the investigators. Each clinician of an intervention group patient received a 1-page summary of patient reported information to cue the provider to symptom issues, concerns and preferences.
Participants in each group were provided with a list of reputable prostate cancer education websites (supplementary Appendix, http://jurology.com/). 18 The sites were linked for immediate online viewing and provided on a printed teaching sheet. In each group participants received any clinic specific educational materials and provider consultations that were the usual preparation for a decision.
Research assistants prompted participants to complete 1-month measures online or by mail according to participant preference at a mean AE SD of 30 AE 7 days from baseline. Participants self-reported any decision and answered the DCS. Medical records were reviewed to verify the decision and document the total number of prostate cancer consultations prior to the 1-month followup. Research assistants were not blinded to study group assignment but all patient reported outcome measures were self-administered.
Instrument
DCS has been used in multiple trials aimed at reducing conflict related to health decisions. 16, 19 In our previous P3P clinical trial we deployed the 16-item, 5-subscale version, which demonstrated total score reliability coefficients of 0.93 to 0.94. 9 Given our adaptation of P3P for low literacy participants in this trial, we selected the 10-item, low literacy version of DCS (see Appendix). Although subscales can be calculated in this version, we report the total score. Our rationale for using the total score was previous total score validity, poor construct validity of the support subscale, lack of evidence of a 4-factor model in men 19 and subscales based on only 2 or 3 items.
Statistical Considerations
Originally the study targeted a sample size of 625 participants and an anticipated 20% attrition rate for an analytical sample of 500 (250 per study group) at 6 months. A planned interim analysis suggested a larger effect size. Under additional circumstances of fewer sites than anticipated, the revised target sample size was 375 participants for an analytical sample of 300 (150 per study group). The study was designed to have 80% power at a 2-sided 0.05 significance level to detect an effect size of 0.325 in DCS scores with the 2-sample t-test.
Baseline characteristics and scores were summarized by group and compared using the t-test or Wilcoxon rank sum test for continuous variables and the Fisher exact or chi-square test for categorical variables. DCS item scores were averaged and multiplied by 25. Scores ranged from 0dlow conflict to 100dhigh conflict. 16 Only DCS questionnaires with complete data were included in analysis and no imputation was performed. The Cronbach a coefficients and the Pearson correlations were calculated. The analytical sample for the primary analysis of DCS between the study groups included all randomized participants with DCS scores at baseline and 1 month regardless of how much intervention the participants received. Figure 1 . Number of participants screened, enrolled, randomized and included in analysis DCS at 1 month was compared between the groups using ANCOVA with linear regression adjusted for baseline DCS. Covariates previously identified as influencing DC (age, education, marital status, working status, income, race/ethnicity, 1-month decisional status, internet as an information source and clinic) plus new covariates (D'Amico risk classification and the number of consultations through 1 month) were assessed univariately and then adjusted on multivariable analysis to improve the precision of estimating the intervention effect. Backward model selection was performed and possible 2-way interactions with the study group were checked. Interactions significant at p 0.1 were included in the final model. Three clinics with fewer than 10 participants each were excluded from univariate analysis of clinic site and from multivariable analysis, resulting in the exclusion of 10 participants. Two-sided type III p values were used to assess overall significance in the model and LS means were used to present the effects of interactions in the multivariable model. We considered p 0.05 statistically significant and between p ¼ 0.05 and p ¼ 0.1 marginally significant. Analyses were performed in SASÒ, version 9.4.
RESULTS
A total of 392 men (71% consent rate) were enrolled in study and randomized, including 198 to P3P and 194 to UC, from September 2013 to April 2016 ( fig. 1) , when the target sample was reached. A total of 305 men, including 152 in the P3P group and 153 in the UC group, returned the 1-month DCS questionnaire for a 78% retention rate. Table 1 lists the demographic and clinical characteristics as well as the use of internet information prior to the target consultation, D'Amico risk classification and clinic sites. There were no baseline group differences. The analytical sample consisted of 276 men with complete DCS data at baseline and 1 month. The groups remained balanced at 1 month except for age since men 60 years old or older were significantly more likely to return 1-month measures (p ¼ 0.05).
Baseline DCS scores did not differ by group with an overall median of 45 (mean 43 AE 25). This level of mean score has been associated with feeling unsure about following through with a decision. 16 Decisional control preferences and decision making stages were similar between the groups (table 2). Our sample majority preferred to share decision making with the physician and they were thinking about the options at the time of study enrollment. DCS had good internal consistency with an a coefficient of 0.88 and 0.89 at baseline and 1 month, respectively. The Pearson correlation between baseline and 1-month DCS scores was 0.27, indicating a significant but weak correlation (p <0.0001).
By the 1-month followup all 305 participants except 1 in the intervention group had attended a physician consultation, 237 (78%) had attended 2 or more consultations and 269 (88%) had made a care decision. In the intervention and UC groups the median 1-month DCS scores were 0 and 0 (mean 10.9 AE 16.7 and 9.9 AE 18.0), respectively. On univariate ANCOVA there was no significant difference by group in DCS score (table 3). A higher DCS score was associated with not working, lower income, no decision by 1 month and lower D'Amico risk. DC varied significantly between sites with the greatest conflict reported by participants enrolled at Emory University Hospital.
In the multivariable model the P3P intervention group reported a DCS score at 1 month that was lower by an estimated 5 units (95% CI 0.59e9.40, p ¼ 0.03) than the score of the usual care group. A higher DCS score was associated with lower income, not making a decision by 1 month, low D'Amico risk and clinic site. Marginally significant interaction was detected between study group and marital status (p ¼ 0.06), suggesting that single men in the intervention group had lower DC than all other participants ( fig. 2, a) . Another marginal interaction was observed between study group and the number of consultations (p ¼ 0.07), indicating that fewer than 2 consultations in the usual care group resulted in higher DC than that of all other participants ( fig. 2, b) .
DISCUSSION
In a second multicenter randomized trial the P3P of men with clinically LPC significantly reduced DC when most men were contemplating an approach to treatment during the few weeks after biopsy. A racially diverse sample was enrolled with typical ages for LPC diagnoses and the D'Amico risk classifications were distributed as expected. 20 Given that eligibility was limited to men who had 1 post-biopsy consultation, we are confident that we enrolled men at the earliest point during decision making.
The t-test of DCS scores at 1 month revealed no differences between the study groups. Unlike other studies in which conflict was measured immediately (the same day) after interventions, 21,22 our trial focused on the conflict experienced during the nearterm decision making period, which was approximated to 1 month after enrollment. As noted in our previous multicenter trial of P3P, demographics and clinical situations were influential during this decision making period with regard to DC. 9 This multivariable analysis revealed such an influence. When it was adjusted for, the P3P intervention significantly reduced decisional conflict. Other investigative groups have found positive effects of a decision aid for localized prostate cancer 23, 24 but not in a geographically and racially diverse sample in the United States.
Marital status and income were influential predictors of DC. To our knowledge no other publication has described marital status as a predictor of the outcome of DCS. The interaction between study group and marital or partner status suggests that Figure 2 shows interaction effects.
P3P had a stronger benefit in single men, who may have had less help with information gathering. Alternatively being in a relationship may have created more conflict as the man considered another person relative to survival and adverse outcomes. to our knowledge no other investigative group has analyzed and reported the influence of income on outcomes. Yet our findings reveal income as an important predictor of DC as an independent variable and in interaction analysis with study group. Having an annual household income of $40,000 or less was associated with higher DC, again indicating that men with fewer resources were at a disadvantage. No decision by 1 month was a strong predictor of the DCS score. Men who remained undecided were likely experiencing more DC. Men who sought consultation from more than 1 provider between study entry and 1 month reported less DC. Further, the interaction between the number of consultations and the study group revealed a DC jeopardy in men in the control group who had only 1 consultation. The intervention provided men who had only 1 consultation with a result similar to that in men with multiple consultations in either group. Clearly exposure to multiple consultations with specialists had a beneficial effect on DC. Personnel in health systems will want to consider methods of providing at least 2 consultations.
The differences in DC between clinic sites were likely related to unknown variables or to unexplored relationships between known variables. Emory University Hospital stands out as a site associated with higher 1-month DC. However, there are no obvious explanations as the site was similar to other academically affiliated urban sites. In the first P3P trial we found that site differences in baseline DC were explained by the distinct sociodemographic characteristics of the men at various sites. 25 Further analysis of such factors is warranted for these new trial data.
Finally, D'Amico risk classification was among the strong covariates influencing the DCS score. Given the importance of the new AUA guidelines 1 and the increasing number of men with low risk disease who are offered active surveillance, our findings illustrate this contemporary dilemma. Men with more options may experience higher conflict. Men with intermediate or high risk disease may also choose among options but typically all of them are active treatments.
Study limitations include 1) the nonblinded trial design as P3P delivers an intervention to patients and clinicians, and 2) the fact that significantly fewer men in the younger group (age less than 60 years) returned a 1-month outcome measure. Thiel et al found a similar age disparity for return of quality of life questionnaires after prostatectomy. 26 Older men may feel more obligated to follow through with a previous agreement. Also, we excluded the lowest accruing sites from the final analytical sample, which were mainly independent or nonnetworked practices. Our results are most pertinent to larger health network sites. Finally, we selected the low literacy version of DCS to meet the needs of a diverse sample of men. The fewer items and fewer response options resulted in a total median 1-month score of 0, perhaps limiting the ability of the questionnaire to discriminate among levels of conflict. Future research is warranted to understand more about reaching men with limited resources. Little support is available for partners of men with LPC, which is a future development area. Further, P3P could be redesigned to provide optional versions, including basic and advanced versions for men and/or partners with low and high literacy or those who may or may not be internet savvy.
Providing clinic access through an internet connected device can be accomplished along with headsets. Clinicians are welcome to view a demonstration site (https://p3p.cirg.washington.edu/demo) and refer patients to the active link (https://p3p4me. org/).
CONCLUSIONS
In a multi-institutional sample P3P demonstrated a beneficial effect in men with LPC as they engaged in decision making on how to manage cancer. Other variables impacted conflict and modified the P3P effect, notably the risk level and the resources of the men. This aid to shared decision making may help support men recently diagnosed with LPC. 
EDITORIAL COMMENTS
The paradigm of shared decision making is becoming ever more entrenched in the patient-provider dyad for decisions with multiple acceptable alternatives. 1 An increasing understanding of the widely variable degree to which patients ascribe value to different aspects of treatments and expected outcomes has contributed to the widespread acceptance of this approach by patients, physicians and policymakers. Despite the acceptance of shared decision making in theory, providers face numerous barriers to executing effective shared decision making in practice. Decision aides, such as the one studied in this unblinded, randomized, multicenter trial for prostate cancer treatment decisions, are useful tools to facilitate necessary components of shared decision making. They include gathering information to understand treatment choices and assessing patient values and preferences in relation to the options. 2 Clearly, however, patients vary in the ability and desire to engage in shared decision making. Decision aides must be tailored to match individual patient preferences for participating in shared decision making. We must also remember the critical role of consulting physicians in creating an environment where patients are able to make decisions about their health that are aligned with their personal values and preferences.
